银屑病系统治疗药物严重感染风险比较
基于美国两个大型保险索赔数据库的观察性队列研究,纳入银屑病系统治疗新用户,比较阿维A、阿达木单抗、阿普斯特、依那西普、英夫利西单抗、甲氨蝶呤和乌司奴单抗的严重感染风险。倾向评分匹配后,阿普斯特、依那西普和乌司奴单抗的严重感染率低于甲氨蝶呤,阿维A的蜂窝织炎风险高于甲氨蝶呤。
要点
- 阿普斯特、依那西普和乌司奴单抗的严重感染率低于甲氨蝶呤。
- 阿维A的蜂窝织炎风险显著高于甲氨蝶呤。
- 阿达木单抗和英夫利西单抗的严重感染率与甲氨蝶呤无差异。
核心结论
- 在银屑病系统治疗患者中,阿普斯特、依那西普和乌司奴单抗新用户的严重感染率低于甲氨蝶呤用户。
- 阿维A用户的蜂窝织炎风险显著高于甲氨蝶呤用户。
研究设计与样本
- 观察性队列研究,使用美国两个大型保险索赔数据库(Optum Clinformatics Data Mart 和 Truven MarketScan),时间范围为2003年1月1日至2015年9月30日。
- 纳入银屑病诊断且为新使用系统药物(阿维A、阿达木单抗、阿普斯特、依那西普、英夫利西单抗、甲氨蝶呤或乌司奴单抗)的患者。
- 采用倾向评分1:1配对调整混杂因素,并用固定效应分析合并两个数据库的结果。
主要发现
- Optum数据库纳入31 595例患者,Truven数据库纳入76 112例患者。
- 与甲氨蝶呤相比,阿普斯特的严重感染风险降低(HR 0.50;95% CI 0.26-0.94)。
- 与甲氨蝶呤相比,依那西普的严重感染风险降低(HR 0.75;95% CI 0.61-0.93)。
- 与甲氨蝶呤相比,乌司奴单抗的严重感染风险降低(HR 0.65;95% CI 0.47-0.89)。
- 与甲氨蝶呤相比,阿维A的蜂窝织炎风险增加(PS调整HR 1.76;95% CI 1.11-2.80)。
临床怎么用
- 在银屑病系统治疗选择时,可参考严重感染风险差异,阿普斯特、依那西普和乌司奴单抗的严重感染率低于甲氨蝶呤。
- 使用阿维A时需警惕蜂窝织炎风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is a need for better understanding of the comparative safety of systemic medications used in the treatment of psoriasis. OBJECTIVE: To compare the risk of serious infection associated with biologic and nonbiologic systemic medications in patients with psoriasis. DESIGN, SETTING, AND PARTICIPANTS: An observational cohort study was conducted using medical and outpatient pharmacy claims from 2 large US health insurance claims databases from January 1, 2003, through September 30, 2015. We included patients with a diagnosis of psoriasis who were new users of systemic medications for psoriasis. EXPOSURES: Prescription claims for acitretin, adalimumab, apremilast, etanercept, infliximab, methotrexate, or ustekinumab. MAIN OUTCOMES AND MEASURES: The primary outcome was serious infection, defined by inpatient discharge diagnosis International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. Cox proportional hazards regression was used to compare rates of serious infection for each exposure (acitretin, adalimumab, apremilast, etanercept, infliximab, and ustekinumab) with the referent group (methotrexate). We used pairwise 1:1 propensity score (PS) matching to adjust for potential confounders, which were assessed during a 180-day baseline period prior to study drug initiation. Results from the 2 databases were pooled via fixed-effects analysis. RESULTS: The databases included 31 595 patients in the Optum Clinformatics Data Mart and 76 112 patients in Truven MarketScan who were new users of acitretin, adalimumab, apremilast, etanercept, infliximab, methotrexate, and ustekinumab. Users of acitretin, apremilast, infliximab, and methotrexate were older and had higher baseline comorbidity scores than subcutaneous biologic users (adalimumab, etanercept, and ustekinumab). The pooled PS-matched analysis yielded a decreased rate of overall serious infection in users of apremilast (hazard ratio [HR], 0.50; 95% CI, 0.26-0.94), etanercept (HR, 0.75; 95% CI, 0.61-0.93), and ustekinumab (HR, 0.65; 95% CI, 0.47-0.89) compared with methotrexate. We did not find a different rate of overall serious infection among users of acitretin, adalimumab, and infliximab compared with methotrexate. Subanalysis by type of serious infection showed a significantly increased risk of cellulitis among users of acitretin compared with methotrexate (PS-adjusted HR, 1.76; 95% CI, 1.11-2.80). CONCLUSIONS AND RELEVANCE: Among patients with psoriasis treated with systemic medications in 2 large US claims databases, new users of apremilast, etanercept, and ustekinumab had a decreased rate of serious infection compared with methotrexate.
引用
- Dommasch ED, Kim SC, Lee MP, et al. Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis. JAMA Dermatol. 2019. PMID: 31075163. doi:10.1001/jamadermatol.2019.1121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。